Bainco International Investors increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 4.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,550 shares of the biopharmaceutical company’s stock after buying an additional 4,840 shares during the period. Bainco International Investors’ holdings in Bristol-Myers Squibb were worth $7,110,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Blue Chip Partners Inc. boosted its stake in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 15 shares during the last quarter. Chilton Investment Co. LLC raised its position in Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 26 shares during the last quarter. Greenleaf Trust raised its position in Bristol-Myers Squibb by 0.4% during the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 39 shares during the last quarter. Finally, Keel Point LLC raised its position in Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 39 shares during the last quarter. Institutional investors own 69.67% of the company’s stock.
Bristol-Myers Squibb Co (NYSE BMY) opened at $62.81 on Friday. The stock has a market capitalization of $102,800.00, a P/E ratio of 24.73, a P/E/G ratio of 2.29 and a beta of 1.18. Bristol-Myers Squibb Co has a fifty-two week low of $46.01 and a fifty-two week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the company posted $0.77 earnings per share. Bristol-Myers Squibb’s revenue was up 6.7% compared to the same quarter last year. equities analysts anticipate that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is 62.99%.
Several equities analysts have recently weighed in on the stock. UBS Group reaffirmed a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price target on the stock in a research note on Monday, October 9th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Finally, Citigroup boosted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a report on Wednesday, October 18th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $65.05.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Bainco International Investors” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/01/14/bainco-international-investors-has-7-11-million-position-in-bristol-myers-squibb-co-bmy-updated-updated.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.